CTOR (Citius Oncology) Asset Impairment Charge : $0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Citius Oncology Asset Impairment Charge?

Citius Oncology's Asset Impairment Charge for the six months ended in Sep. 2024 was $0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil.

Citius Oncology Asset Impairment Charge Historical Data

The historical data trend for Citius Oncology's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Citius Oncology Asset Impairment Charge Chart

Citius Oncology Annual Data

Trend

Sep22

Sep23

Sep24

Asset Impairment Charge

Citius Oncology Semi-Annual Data
	Sep22	Sep23	Sep24
Asset Impairment Charge	-	-	-

Citius Oncology Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Asset Impairment Charge for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil.

Citius Oncology Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Citius Oncology's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Citius Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Citius Oncology Inc (NAS:CTOR) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

N/A

Address

420 Lexington Ave, Suite 2446, New York, NY, USA, 10170

Website

Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.

Citius Oncology Headlines

From GuruFocus

Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

By PRNewswire • 12-27-2024